The Impact of COVID-19
on Clinical Research



What is the

Heart Failure Collaboratory (HFC)?

Efficiency of clinical trials and evidence generation in heart failure and foster development of therapies by creating a collaborative environment in which FDA, government agencies including NIH and CMS, and the heart failure community can interact to optimize innovation and advancement of new therapeutic products. HFC has established five working groups to tackle individual issues in clinical trials and fostering the development of effective heart failure therapies.

The Heart Failure Collaboratory is a public-private partnership with the FDA and the consortium to help foster the development of new products for heart failure.

Recent Publications

Access our latest publications, downloads and meeting notes.
Barriers to Clinical Trial Efficiency and Patient Access
Clinical trial inefficiency and lack of patient access to novel therapies have been identified as key barriers to successful heart failure innovation.
Clinical Trials in the Landscape of COVID-19
The HF Collaboratory Statement provides recommendations on HF clinical trials by outlining a number of guiding principles and possible trial conduct solutions for the COVID-19 pandemic.
Improving Heart Failure Therapeutics Development in the United States
Summarizes the discussions, challenges and opportunities, and makes recommendations to achieve improved efficiency in clinical trials and the development of effective heart failure therapies.